sur SANOFI-AVENTIS (EPA:SAN)
Sanofi's VaxRabeo Rabies Vaccine Gains EU Approval for All Ages
On November 19, 2026, Sanofi announced the European Commission's approval of VaxRabeo, a next-generation rabies vaccine for all age groups. This marks VaxRabeo's first marketing authorization, following a positive opinion by the European Medicines Agency. The vaccine is designed for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) and is developed using advanced Vero-cell technology enhancing its safety and shelf life.
Rabies, a zoonotic disease causing over 59,000 deaths annually, is preventable by vaccination. VaxRabeo demonstrated effective antibody responses comparable to existing vaccines, in PrEP and PEP scenarios with similar immunogenicity and safety profiles.
Sanofi emphasizes this development as a pivotal milestone in their ongoing commitment to combat rabies. With VaxRabeo's approval, the company aims to enhance global healthcare systems with modern preventive tools against rabies.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SANOFI-AVENTIS